C225 WITH CHEMORADIATION FOR NSCLC

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。根据安全性和依从性确定同时应用西妥昔单抗和放化疗的可行性。1)估计研究方案中患者的治疗反应率；2)估计研究方案中患者的总存活率；3)估计研究方案中患者的疾病进展时间；以及4)调查EGFR表达与毒性、反应、总存活率和进展之间的关系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine the feasibility of concurrent Cetuximab and chemoradiation as measured by safety and compliance. 1) Estimate the treatment response rate of patients on the study regimen; 2) Estimate overall survival of patients on the study regimen; 3) Estimate the time to disease progression of patients on the study regimen; and 4) Investigate associates between EGFR expression and toxicity, response, overall survival and progression.